Similares a ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More | HCPLive Expert Interviews

20 vecinos (text_768) · 55 views · HCPLive · Estados Unidos


★	ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	55	Estados Unidos
16	Mepolizumab Add-On Reduces COPD Exacerbations in Triple-Therapy Patients \| ATS 2026	HCPLive @hcplivenews	1.2K	Estados Unidos	86
9	88% Culture Conversion in MAC Lung Disease—Is Earlier ALIS the Answer? \| #ats2026	HCPLive @hcplivenews	909	Estados Unidos	87
19	Efdoralprin Alfa Normalizes Alpha-1 Antitrypsin Levels I #ats2026	HCPLive @hcplivenews	548	Estados Unidos	85
20	La Universitat se suma al Dia Europeu de Dèficit d'Alfa-1	Universitat de València @universitatvalencia	481	España	85
10	Inhaled Treprostinil for IPF: TETON-1 Phase 3 Results With Steven Nathan, MD \| ATS 2026	HCPLive @hcplivenews	301	Estados Unidos	86
3	Ralinepag Cuts PAH Clinical Worsening Risk by 55%, With Vallerie McLaughlin, MD \| ATS 2026	HCPLive @hcplivenews	290	Estados Unidos	89
4	Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD	HCPLive @hcplivenews	198	Estados Unidos	89
15	Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results	HCPLive @hcplivenews	156	Estados Unidos	86
8	What the Phase 3 AD109 Data Mean for Sleep Apnea, With Patrick John Strollo, MD	HCPLive @hcplivenews	142	Estados Unidos	87
14	REACH Study: Broncho-Vaxom (OM-85) Cuts Recurrent Respiratory Tract Infections	HCPLive @hcplivenews	134	Estados Unidos	86
6	AD109 Shows Promise as Oral Agent for Obstructive Sleep Apnea, With Patrick John Strollo, MD	HCPLive @hcplivenews	129	Estados Unidos	88
17	Tezepelumab Reduced Severe Asthma Exacerbations Across Phenotypes \| ATS 2026	HCPLive @hcplivenews	122	Estados Unidos	86
5	Phase 3b ENCORE: ALIS Improves MAC Lung Disease Outcomes \| ATS 2026	HCPLive @hcplivenews	117	Estados Unidos	88
13	Mepolizumab Reduced COPD Hospitalizations in Eosinophilic Disease \| ATS 2026 With Gerard Criner, MD	HCPLive @hcplivenews	113	Estados Unidos	86
2	AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD	HCPLive @hcplivenews	105	Estados Unidos	91
12	Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results	HCPLive @hcplivenews	82	Estados Unidos	86
1	ATS 2026 Asthma Updates: Tezepelumab, Dupilumab, OCS Reduction & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	70	Estados Unidos	91
7	SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026	HCPLive @hcplivenews	48	Estados Unidos	87
18	Pegtarazimod Cuts Oxygen Need in Hospitalized COPD Patients \| ATS 2026 \| Gerald Criner, MD	HCPLive @hcplivenews	29	Estados Unidos	85
11	Predicting Post-BLVR Pneumothorax With Quantitative CT \| ATS 2026	HCPLive @hcplivenews	23	Estados Unidos	86